Ultrasound-guided direct delivery of 3-bromopyruvate blocks tumor progression in an orthotopic mouse model of human pancreatic cancer
- 26 March 2013
- journal article
- research article
- Published by Springer Nature in Targeted Oncology
- Vol. 8 (2) , 145-151
Abstract
Studies in animal models of cancer have demonstrated that targeting tumor metabolism can be an effective anticancer strategy. Previously, we showed that inhibition of glucose metabolism by the pyruvate analog, 3-bromopyruvate (3-BrPA), induces anticancer effects both in vitro and in vivo. We have also documented that intratumoral delivery of 3-BrPA affects tumor growth in a subcutaneous tumor model of human liver cancer. However, the efficacy of such an approach in a clinically relevant orthotopic tumor model has not been reported. Here, we investigated the feasibility of ultrasound (US) image-guided delivery of 3-BrPA in an orthotopic mouse model of human pancreatic cancer and evaluated its therapeutic efficacy. In vitro, treatment of Panc-1 cells with 3-BrPA resulted in a dose-dependent decrease in cell viability. The loss of viability correlated with a dose-dependent decrease in the intracellular ATP level and lactate production confirming that disruption of energy metabolism underlies these 3-BrPA-mediated effects. In vivo, US-guided delivery of 3-BrPA was feasible and effective as demonstrated by a marked decrease in tumor size on imaging. Further, the antitumor effect was confirmed by (1) a decrease in the proliferative potential by Ki-67 immunohistochemical staining and (2) the induction of apoptosis by terminal deoxynucleotidyl transferase-mediated deoxyuridine 5-triphospate nick end labeling staining. We therefore demonstrate the technical feasibility of US-guided intratumoral injection of 3-BrPA in a mouse model of human pancreatic cancer as well as its therapeutic efficacy. Our data suggest that this new therapeutic approach consisting of a direct intratumoral injection of antiglycolytic agents may represent an exciting opportunity to treat patients with pancreas cancer.Keywords
This publication has 26 references indexed in Scilit:
- Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose MetabolismCell, 2012
- Overcoming drug resistance in pancreatic cancerExpert Opinion on Therapeutic Targets, 2011
- The Pyruvic Acid Analog 3-Bromopyruvate Interferes With the Tetrazolium Reagent MTS in the Evaluation of CytotoxicityASSAY and Drug Development Technologies, 2010
- Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic CancerScience, 2009
- Synergistic Antipancreatic Tumor Effect by Simultaneously Targeting Hypoxic Cancer Cells With HSP90 Inhibitor and Glycolysis InhibitorClinical Cancer Research, 2008
- Meta-Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic CancerJournal of Clinical Oncology, 2007
- Photodynamic Therapy for Pancreatic CancerPancreas, 2007
- Locally Advanced Pancreatic Cancer: Current Therapeutic ApproachThe Oncologist, 2006
- EUS-guided ethanol injection of normal porcine pancreas: a pilot studyGastrointestinal Endoscopy, 2005
- On the Origin of Cancer CellsScience, 1956